She says she plateaued on Zepbound after a quick 20 lb loss and asks others for their take. Retatrutide is still in trials, so the source of the drug is unclear.
Recap by typeshit. Post by Facebook on Facebook.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
9:11
A short clip weighing the approved tirzepatide against retatrutide, which is still in trials, for people over 50.
Medscape reports the pill version of semaglutide for obesity passed 100,000 monthly prescriptions just two months after reaching the market.
Loading…